Tandem Diabetes Care designs, manufactures, and sells automated insulin delivery systems and advanced insulin pumps for people with insulin-dependent diabetes. Founded in 2006 and headquartered in San Diego, California, the company is publicly listed on Nasdaq. Its product line includes the t:slim X2 pump and Tandem Mobi system, both powered by proprietary technology.
The company's core technology, Control-IQ+ with AutoBolus, is a predictive algorithm that automates insulin dosing to improve glucose control and simplify diabetes management. This technology integrates with continuous glucose monitoring systems from Dexcom and Abbott FreeStyle Libre. Tandem characterises Control-IQ+ as the only technology of its kind on the market.
The company's approach emphasises human-centred product design and comprehensive support for both healthcare providers and patients. Its work centres on creating tools that expand possibilities for people managing insulin-dependent diabetes.
